SCHEMBL24258037

SCHEMBL24258037

O=C1COc2ccccc2N1Cc1noc(-c2ccccc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.61
HDAC6 Q9UBN7 2/20 0.61
HDAC4 P56524 1/20 0.61
GRM5 P41594 2/20 0.54
TSHR P16473 2/20 0.51
HDAC8 Q9BY41 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NOTUM Q6P988 1/20 0.45
CHRM1 P11229 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.43
CBX7 O95931 1/20 0.43
CDYL2 Q8N8U2 1/20 0.43
CDYL Q9Y232 1/20 0.43
CDY1; CDY1B Q9Y6F8 1/20 0.43
DRD4 P21917 1/20 0.42
ALOX12 P18054 1/20 0.42
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098202 0.76 HDAC6 (1.00) HDAC1HDAC6HDAC4HDAC8HDAC5
SCHEMBL3641417 0.69 ALDH1A1 (0.58) TSHRL3MBTL1MEN1KMT2AGAA
SCHEMBL474614 0.69 TSHR (0.60) TSHRL3MBTL1MEN1KMT2AGAA
SCHEMBL30808661 0.68 KMT2A (0.68) TSHRMEN1KMT2AGAACBX7
SCHEMBL4970176 0.68 KMT2A (0.68) TSHRMEN1KMT2AGAACBX7
SCHEMBL5338561 0.68 TSHR (0.71) GRM5TSHRL3MBTL1CHRM1MEN1
SCHEMBL31667554 0.68 L3MBTL1 (0.70) TSHRL3MBTL1MEN1KMT2AGAA
SCHEMBL4506469 0.68 ALDH1A1 (0.69) TSHRL3MBTL1MEN1KMT2AGAA
SCHEMBL9686469 0.68 NMT1 (0.41) HDAC1HDAC6HDAC4GRM5TSHR
SCHEMBL8556616 0.67 TSHR (0.65) GRM5TSHRL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 HDAC1 153/4885HDAC6 100/4885HDAC4 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.